largely attributable to the interaction of this agent with non-mineralocor-ticoid steroid receptors, has reduced the enthusiasm for its use. Eplerenone, a specific aldosterone receptor blocker ...

Spironolactone was the first aldosterone receptor antagonist introduced into the US market. The process of its entry was an interesting one. Spironolactone underwent a series of approvals ...

Compared with placebo, sodium zirconium cyclosilicate was associated with less need to lower or discontinue spironolactone.

The FINEARTS-HF trial offered novel clinical insights as one of the few cardiovascular trials to feature such a great proportion of female participants.

and various drugs including angiotensin-converting enzyme inhibitors (ACEis), angiotensin II receptor blockers (ARBs), beta-blockers, aldosterone receptor antagonists, sodium-glucose cotransporter ...